IP Library Granted Patent US 12,408,914
Granted Patent B2
US 12,408,914 · App. 18/484,929 · Granted Sep 9, 2025

Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials

Inventors: Peyton Hopson (Cincinnati, OH); Brody Frost (Fairfield, OH); Madelaine Franzoni (Cincinnati, OH); Michael J. Vendely (Lebanon, OH)
Assignee: CILAG GMBH INTERNATIONAL
A61B17/0644A61B17/068A61B17/07292A61L17/005A61L17/10A61L17/145A61L31/041A61L31/06A61L31/10A61L31/128A61L31/129A61L31/146A61L31/148A61L31/16B29C65/4855B29C65/4885B29C65/52C08L75/04A61B2017/00004A61B2017/00526A61B2017/00867A61B2017/00938A61B2017/00951A61B2017/07271A61L2300/604A61L2400/12A61L2420/02B29L2031/7546C08L2203/02C08L2312/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,408,914
App. No.
18/484,929
Granted
Sep 9, 2025
Kind
B2
Abstract

The disclosed technology includes a bioabsorbable material configured to be delivered to tissue. The material includes a shape-memory polymer compressible in a delivery configuration and configured to swell within a predetermined period of time. The shape-memory polymer includes one or more functional groups for reversible bonding between adjacent functional groups to transition between an approximately linear polymer and an approximately non-linear polymer upon exposure to a stimulation.

Claims (25)

1. A bioabsorbable material configured to be delivered to tissue, the material comprising: a shape-memory polymer compressible in a delivery configuration and configured to swell for a predetermined period of time comprising a range from approximately 0.01 seconds to approximately 120 seconds; wherein the shape-memory polymer comprises one or more functional groups for reversible bonding between adjacent functional groups to transition between an approximately linear polymer and an approximately non-linear polymer upon exposure to a stimulation.

2. The bioabsorbable material of claim 1 , wherein the shape-memory polymer transitions from the delivery configuration to a swollen configuration when exposed to a temperature in a range of about 34° C. to about 40° C.

3. The bioabsorbable material of claim 1 , wherein the stimulation comprises at least one of heat, light, water, electrical, magnetic, electromagnetic, ultrasound, and pH.

4. The bioabsorbable material of claim 3 , wherein the bioabsorbable material has a compression strength of about 50 kPa to about 90 kPa in the delivery configuration, and a compression strength of about 30 kPa to about 70 kPa in the swollen configuration.

5. The bioabsorbable material of claim 1 , wherein the shape-memory polymer comprises a reaction product of a polyol and an isocyanate.

6. The bioabsorbable material of claim 1 , wherein the functional groups comprise a diene and a dienophile moieties, and wherein the shape-memory polymer is configured to reversibly transition upon exposure to a temperature in a range of about 34° C. to about 40° C.

7. The bioabsorbable material of claim 6 , wherein the functional groups comprise at least one of a disulfide moiety and a diselenide moiety, and wherein the shape-memory polymer is configured to reversibly transition upon exposure to at least one of a change in temperature, a change in pH, a reactive oxygen species, or combinations thereof.

8. The bioabsorbable material of claim 1 , wherein the functional groups comprise a styrylpyrene moiety, and wherein the shape-memory polymer is configured to reversibly transition upon exposure to a wavelength of light ranging from about 310 nm to about 450 nm.

9. The bioabsorbable material of claim 1 , wherein the functional groups comprise an azo moiety, and wherein the shape-memory polymer is configured to reversibly transition upon exposure to a temperature above about 60° C.

10. The bioabsorbable material of claim 1 , wherein the functional groups comprise an ortho-nitrobenzyl moiety, and wherein the shape-memory polymer is configured to reversibly transition upon exposure to a wavelength of light ranging from about 310 nm to about 440 nm.

11. The bioabsorbable material of claim 1 , wherein the functional groups comprise a coumarin moiety, wherein the shape-memory polymer is configured to reversibly transition to a first compression strength upon exposure to a wavelength of light ranging from about 200 nm to about 260 nm; and wherein the shape-memory polymer is configured to reversibly transition to a second compression strength upon exposure to a wavelength of light ranging from about 350 nm to about 560 nm.

12. The bioabsorbable material of claim 1 , wherein the functional groups comprise an anthracene moiety, and wherein the shape-memory polymer is configured to reversibly transition to the approximately non-linear configuration upon exposure to a wavelength of light greater than about 300 nm, and transition to the approximately linear configuration upon exposure to a wavelength of light less than about 300 nm.

13. The bioabsorbable material of claim 1 , wherein the bioabsorbable material degrades according to a degradation profile in response to exposure to a fluid comprising at least one of a predetermined temperature, an enzyme-catalyst, and a predetermined pH.

14. The bioabsorbable material of claim 1 , further comprising one or more medical additives configured to remain chemically bonded to the shape-memory polymer.

15. The bioabsorbable material of claim 14 , wherein the one or more medical additives are further configured to be released to or approximate the tissue.

16. A bioabsorbable material configured to be delivered to tissue, the material comprising: a shape-memory polymer compressible in a delivery configuration and configured to swell for a predetermined period of time upon exposure to a stimulation, wherein the predetermined period of time comprises a range from approximately 0.01 seconds to approximately 120 seconds, the shape-memory polymer comprising a polyurethane backbone and one or more functional groups for reversible bonding between adjacent functional groups to transition between an approximately linear polymer to an approximately non-linear polymer.

17. The bioabsorbable material of claim 16 , wherein the stimulation comprises at least one of heat, light, water, electrical, magnetic, electromagnetic, ultrasound, and pH.

18. The bioabsorbable material of claim 16 , wherein the one or more functional groups comprise at least one of a diene and a dienophile moiety, a styrylpyrene moiety, an azo moiety, an ortho-nitrobenzyl moiety, a coumarin moiety, an anthracene moiety, a disulfide moiety, a diselenide moiety, or combinations thereof.

19. A method to form a bioabsorbable material configured to be placed inside a body of a human, the method comprising the steps of: adding, to a polyurethane polymer, a functional group comprising at least one of a diene and a dienophile moiety, a styrylpyrene moiety, an azo moiety, an ortho-nitrobenzyl moiety, a coumarin moiety, an anthracene moiety, a disulfide moiety, a diselenide moiety, or combinations thereof; and chemically bonding the polyurethane polymer and functional groups to form a shape-memory polymer.

20. The method of claim 19 , further comprising the step of: exposing the shape-memory polymer to a stimulation comprising at least one of heat, light, water, electrical, magnetic, electromagnetic, ultrasound, and pH.

21. The method of claim 20 , wherein the shape-memory polymer is configured to reversibly transition between an approximately linear polymer to an approximately non-linear polymer.

22. The method of claim 20 , wherein the shape-memory polymer is compressible in a delivery configuration.

23. The method of claim 19 , wherein the bioabsorbable material comprises a delivery height ranging from about 0.01 mm to about 1 mm when in the delivery configuration.

24. The method of claim 23 , further comprising the step of: increasing a height of the shape-memory polymer to greater than the delivery height.

25. The method of claim 19 , further comprising the step of: exposing the bioabsorbable material to a fluid comprising at least one of a predetermined temperature, an enzyme-catalyst, and a predetermined pH such that the bioabsorbable material degrades according to a degradation profile.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2024
From: HOPSON, PEYTON; FROST, BRODY; FRANZONI, MADELAINE; VENDELY, MICHAEL J.
To: CILAG GMBH INTERNATIONAL
Reel/Frame 068577/0690 →
Continuity (2)
Provisional Application 63522660 · Jun 22, 2023
Related Publication 20240423617A1 · Dec 26, 2024
References Cited (262)
US 4264743A · Maruyama · 1981 [cited by applicant]
US 5151315A · Ponnet · 1992 [cited by applicant]
US 6325810B1 · Hamilton · 2001 [cited by applicant]
US 8303625B2 · Lendlein · 2012 [cited by examiner]
US 8393514B2 · Shelton, IV et al. · 2013 [cited by applicant]
US 8496683B2 · Prommersberger · 2013 [cited by applicant]
US 8657176B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8746535B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8752699B2 · Morgan et al. · 2014 [cited by applicant]
US 8777004B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8783542B2 · Riestenberg et al. · 2014 [cited by applicant]
US 8814025B2 · Miller et al. · 2014 [cited by applicant]
US 8834522B2 · Lendlein · 2014 [cited by examiner]
US 8851354B2 · Swensgard et al. · 2014 [cited by applicant]
US 8857694B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8864009B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8893949B2 · Shelton, IV et al. · 2014 [cited by applicant]
US 8899463B2 · Schall et al. · 2014 [cited by applicant]
US 8925782B2 · Shelton, IV · 2015 [cited by applicant]
US 8978956B2 · Schall et al. · 2015 [cited by applicant]
US 9016542B2 · Shelton, IV et al. · 2015 [cited by applicant]
US 9113865B2 · Shelton, IV et al. · 2015 [cited by applicant]
US 9168038B2 · Shelton, IV et al. · 2015 [cited by applicant]
US 9198662B2 · Barton et al. · 2015 [cited by applicant]
US 9204880B2 · Baxter, III et al. · 2015 [cited by applicant]
US 9211120B2 · Scheib et al. · 2015 [cited by applicant]
US 9220500B2 · Swayze et al. · 2015 [cited by applicant]
US 9220501B2 · Baxter, III et al. · 2015 [cited by applicant]
US 9272406B2 · Aronhalt et al. · 2016 [cited by applicant]
US 9295464B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9301753B2 · Aldridge et al. · 2016 [cited by applicant]
US 9301755B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9307987B2 · Swensgard et al. · 2016 [cited by applicant]
US 9307989B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9314247B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9320523B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9332984B2 · Weaner et al. · 2016 [cited by applicant]
US 9358005B2 · Shelton, IV et al. · 2016 [cited by applicant]
US 9386984B2 · Aronhalt et al. · 2016 [cited by applicant]
US 9386988B2 · Baxter, III et al. · 2016 [cited by applicant]
US 9480476B2 · Aldridge et al. · 2016 [cited by applicant]
US 9566061B2 · Aronhalt et al. · 2017 [cited by applicant]
US 9572574B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9572577B2 · Lloyd et al. · 2017 [cited by applicant]
US 9585657B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9592050B2 · Schmid et al. · 2017 [cited by applicant]
US 9629814B2 · Widenhouse et al. · 2017 [cited by applicant]
US 9693777B2 · Schellin et al. · 2017 [cited by applicant]
US 9700317B2 · Aronhalt et al. · 2017 [cited by applicant]
US 9724098B2 · Baxter, III et al. · 2017 [cited by applicant]
US 9757124B2 · Schellin et al. · 2017 [cited by applicant]
US 9770245B2 · Swayze et al. · 2017 [cited by applicant]
US 9775608B2 · Aronhalt et al. · 2017 [cited by applicant]
US 9788834B2 · Schmid et al. · 2017 [cited by applicant]
US 9795383B2 · Aldridge et al. · 2017 [cited by applicant]
US 9795384B2 · Weaner et al. · 2017 [cited by applicant]
US 9801634B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9808247B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9826978B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9833236B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9833238B2 · Baxter, III et al. · 2017 [cited by applicant]
US 9833242B2 · Baxter, III et al. · 2017 [cited by applicant]
US 9839420B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9839422B2 · Schellin et al. · 2017 [cited by applicant]
US 9839423B2 · Vendely et al. · 2017 [cited by applicant]
US 9844372B2 · Shelton, IV et al. · 2017 [cited by applicant]
US 9844376B2 · Baxter, III et al. · 2017 [cited by applicant]
US 9848875B2 · Aronhalt et al. · 2017 [cited by applicant]
US 9861361B2 · Aronhalt et al. · 2018 [cited by applicant]
US 9883861B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 9884456B2 · Schellin et al. · 2018 [cited by applicant]
US 9918716B2 · Baxter, III et al. · 2018 [cited by applicant]
US 9924944B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 9924947B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 9962161B2 · Scheib et al. · 2018 [cited by applicant]
US 9974538B2 · Baxter, III et al. · 2018 [cited by applicant]
US 10028743B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 10052104B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 10064624B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 10136890B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 10149682B2 · Shelton, IV et al. · 2018 [cited by applicant]
US 10182819B2 · Shelton, IV · 2019 [cited by applicant]
US 10213198B2 · Aronhalt et al. · 2019 [cited by applicant]
US 10258330B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10258332B2 · Schmid et al. · 2019 [cited by applicant]
US 10265072B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10271849B2 · Vendely et al. · 2019 [cited by applicant]
US 10285700B2 · Scheib · 2019 [cited by applicant]
US 10335148B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10335150B2 · Shelton, IV · 2019 [cited by applicant]
US 10390823B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10398436B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10426481B2 · Aronhalt et al. · 2019 [cited by applicant]
US 10441285B2 · Shelton, IV et al. · 2019 [cited by applicant]
US 10588623B2 · Schmid et al. · 2020 [cited by applicant]
US 10603039B2 · Vendely et al. · 2020 [cited by applicant]
US D882782S · Shelton, IV et al. · 2020 [cited by applicant]
US 10617417B2 · Baxter, III et al. · 2020 [cited by applicant]
US 10617418B2 · Barton et al. · 2020 [cited by applicant]
US 10624861B2 · Widenhouse et al. · 2020 [cited by applicant]
US D885574S · Shelton, IV et al. · 2020 [cited by applicant]
US 10667808B2 · Baxter, III et al. · 2020 [cited by applicant]
US 10695061B2 · Vendely et al. · 2020 [cited by applicant]
US 10743877B2 · Shelton, IV et al. · 2020 [cited by applicant]
US 10779817B2 · Shelton, IV et al. · 2020 [cited by applicant]
US 10799237B2 · Shelton, IV et al. · 2020 [cited by applicant]
US 10813637B2 · Shelton, IV et al. · 2020 [cited by applicant]
US 10835249B2 · Schellin et al. · 2020 [cited by applicant]
US 10869669B2 · Shelton, IV et al. · 2020 [cited by applicant]
US 10905418B2 · Shelton, IV et al. · 2021 [cited by applicant]
US 10952724B2 · Shelton, IV et al. · 2021 [cited by applicant]
US 10959721B2 · Shelton, IV et al. · 2021 [cited by applicant]
US 10966713B2 · Shelton, IV et al. · 2021 [cited by applicant]
US 10980533B2 · Shelton, IV et al. · 2021 [cited by applicant]
US 10980539B2 · Harris et al. · 2021 [cited by applicant]
US D920513S · Shelton, IV et al. · 2021 [cited by applicant]
US 11006950B2 · Harris et al. · 2021 [cited by applicant]
US 11020115B2 · Scheib et al. · 2021 [cited by applicant]
US 11058425B2 · Widenhouse et al. · 2021 [cited by applicant]
US 11083452B2 · Schmid et al. · 2021 [cited by applicant]
US 11118025B2 · Donners · 2021 [cited by examiner]
US 11154296B2 · Aronhalt et al. · 2021 [cited by applicant]
US 11154297B2 · Swayze et al. · 2021 [cited by applicant]
US 11155946B2 · Vendely et al. · 2021 [cited by applicant]
US 11185325B2 · Shelton, IV et al. · 2021 [cited by applicant]
US D940318S · Shelton, IV et al. · 2022 [cited by applicant]
US 11291449B2 · Swensgard et al. · 2022 [cited by applicant]
US 11337698B2 · Baxter et al. · 2022 [cited by applicant]
US 11395651B2 · Shelton, IV et al. · 2022 [cited by applicant]
US D960364S · Shelton, IV et al. · 2022 [cited by applicant]
US 11406377B2 · Schmid et al. · 2022 [cited by applicant]
US 11406378B2 · Baxter et al. · 2022 [cited by applicant]
US 11446027B2 · Harris et al. · 2022 [cited by applicant]
US 11446032B2 · Harris et al. · 2022 [cited by applicant]
US 11471158B2 · Harris et al. · 2022 [cited by applicant]
US 11504116B2 · Schmid et al. · 2022 [cited by applicant]
US 11504125B2 · Shelton, IV et al. · 2022 [cited by applicant]
US 11534168B2 · Harris et al. · 2022 [cited by applicant]
US 11534169B2 · Harris et al. · 2022 [cited by applicant]
US 11540824B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11540832B2 · Harris et al. · 2023 [cited by applicant]
US 11540833B2 · Harris et al. · 2023 [cited by applicant]
US 11553915B2 · Harris et al. · 2023 [cited by applicant]
US 11559496B2 · Widenhouse et al. · 2023 [cited by applicant]
US 11571215B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11583277B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11602340B2 · Schmid et al. · 2023 [cited by applicant]
US 11602341B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11612396B2 · Harris et al. · 2023 [cited by applicant]
US 11638584B2 · Harris et al. · 2023 [cited by applicant]
US 11642130B2 · Harris et al. · 2023 [cited by applicant]
US 11648007B2 · Harris et al. · 2023 [cited by applicant]
US 11672536B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11672537B2 · Harris et al. · 2023 [cited by applicant]
US 11678883B2 · Harris et al. · 2023 [cited by applicant]
US 11684360B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11690617B2 · Harris et al. · 2023 [cited by applicant]
US 11701114B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11707279B2 · Harris et al. · 2023 [cited by applicant]
US 11737754B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11793509B2 · Baxter, III et al. · 2023 [cited by applicant]
US 11812965B2 · Baxter, III et al. · 2023 [cited by applicant]
US 11839374B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11849950B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11849952B2 · Shelton, IV · 2023 [cited by applicant]
US 11850310B2 · Shelton, IV et al. · 2023 [cited by applicant]
US D1013171S · Shelton, IV et al. · 2024 [cited by applicant]
US 11864765B2 · Shelton, IV et al. · 2024 [cited by applicant]
US 11896226B2 · Shelton, IV et al. · 2024 [cited by applicant]
US 11911027B2 · Aronhalt et al. · 2024 [cited by applicant]
US 11918210B2 · Shelton, IV et al. · 2024 [cited by applicant]
US 11925354B2 · Shelton, IV et al. · 2024 [cited by applicant]
US 11957795B2 · Schmid et al. · 2024 [cited by applicant]
US 20050113510A1 · Feldstein · 2005 [cited by applicant]
US 20090090763A1 · Zemlok et al. · 2009 [cited by applicant]
US 20100116868A1 · Prommersberger · 2010 [cited by applicant]
US 20120080336A1 · Shelton, IV et al. · 2012 [cited by applicant]
US 20120080344A1 · Shelton, IV · 2012 [cited by applicant]
US 20120080478A1 · Morgan et al. · 2012 [cited by applicant]
US 20120080498A1 · Shelton, IV et al. · 2012 [cited by applicant]
US 20130153641A1 · Shelton, IV et al. · 2013 [cited by applicant]
US 20130211520A1 · Hoganson · 2013 [cited by applicant]
US 20130234372A1 · Almutairi · 2013 [cited by applicant]
US 20130256374A1 · Shelton, IV · 2013 [cited by applicant]
US 20130256375A1 · Shelton, IV · 2013 [cited by applicant]
US 20130256380A1 · Schmid et al. · 2013 [cited by applicant]
US 20140166726A1 · Schellin · 2014 [cited by applicant]
US 20140291379A1 · Schellin et al. · 2014 [cited by applicant]
US 20150217028A1 · Pacetti · 2015 [cited by applicant]
US 20150282810A1 · Shelton, IV · 2015 [cited by applicant]
US 20150313594A1 · Shelton, IV et al. · 2015 [cited by applicant]
US 20150351753A1 · Shelton, IV · 2015 [cited by applicant]
US 20160074040A1 · Widenhouse et al. · 2016 [cited by applicant]
US 20160183944A1 · Swensgard et al. · 2016 [cited by applicant]
US 20160199063A1 · Mandakolathur Vasudevan et al. · 2016 [cited by applicant]
US 20170049448A1 · Widenhouse · 2017 [cited by applicant]
US 20170055986A1 · Harris · 2017 [cited by applicant]
US 20170232157A1 · Rege · 2017 [cited by applicant]
US 20180116658A1 · Aronhalt, IV et al. · 2018 [cited by applicant]
US 20180140299A1 · Weaner et al. · 2018 [cited by applicant]
US 20180235626A1 · Shelton, IV · 2018 [cited by applicant]
US 20180250434A1 · Ker · 2018 [cited by applicant]
US 20190059889A1 · Shelton, IV et al. · 2019 [cited by applicant]
US 20190090871A1 · Shelton, IV et al. · 2019 [cited by applicant]
US 20190133578A1 · Kriksunov et al. · 2019 [cited by applicant]
US 20190254667A1 · Vendely et al. · 2019 [cited by applicant]
US 20190254668A1 · Vendely et al. · 2019 [cited by applicant]
US 20190254669A1 · Shelton, IV et al. · 2019 [cited by applicant]
US 20190269400A1 · Mandakolathur Vasudevan et al. · 2019 [cited by applicant]
US 20200085435A1 · Shelton, IV et al. · 2020 [cited by applicant]
US 20200187943A1 · Shelton, IV et al. · 2020 [cited by applicant]
US 20200376158A1 · Moore · 2020 [cited by applicant]
US 20210059661A1 · Schmid et al. · 2021 [cited by applicant]
US 20210077107A1 · Harris · 2021 [cited by applicant]
US 20210085315A1 · Aronhalt et al. · 2021 [cited by applicant]
US 20210259681A1 · Shelton, IV et al. · 2021 [cited by applicant]
US 20210259986A1 · Widenhouse et al. · 2021 [cited by applicant]
US 20210267589A1 · Swayze et al. · 2021 [cited by applicant]
US 20210282767A1 · Shelton, IV et al. · 2021 [cited by applicant]
US 20210290226A1 · Mandakolathur Vasudevan et al. · 2021 [cited by applicant]
US 20220000481A1 · Sung · 2022 [cited by examiner]
US 20220151611A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220167970A1 · Aronhalt et al. · 2022 [cited by applicant]
US 20220175370A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220175372A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220211367A1 · Schmid et al. · 2022 [cited by applicant]
US 20220218348A1 · Swensgard et al. · 2022 [cited by applicant]
US 20220313145A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313245A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313248A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313253A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313255A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313256A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313259A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220313262A1 · Shelton, IV et al. · 2022 [cited by applicant]
US 20220338870A1 · Swayze et al. · 2022 [cited by applicant]
US 20220354495A1 · Baxter, III et al. · 2022 [cited by applicant]
US 20220370684A1 · Nseir Manassa · 2022 [cited by applicant]
US 20230140285A1 · Boudreaux · 2023 [cited by applicant]
US 20230210525A1 · Shelton, IV et al. · 2023 [cited by applicant]
US 20230301656A1 · Seow · 2023 [cited by applicant]
US 20230301657A1 · Zeiner et al. · 2023 [cited by applicant]
US 20230301674A1 · Rector et al. · 2023 [cited by applicant]
US 20230301675A1 · Seow et al. · 2023 [cited by applicant]
US 20230320742A1 · Bakos et al. · 2023 [cited by applicant]
EP 3135323A1 · 2017 [cited by applicant]
WO 2006060482A2 · 2006 [cited by applicant]
WO 2009020797A2 · 2009 [cited by applicant]
WO 2014004205A1 · 2014 [cited by applicant]
WO 2014004208A1 · 2014 [cited by applicant]
WO 2015095755A1 · 2015 [cited by applicant]
WO 2015191219A1 · 2015 [cited by applicant]
WO 2016153903A2 · 2016 [cited by applicant]
WO 2017040189A1 · 2017 [cited by applicant]
WO 2018229574A1 · 2018 [cited by applicant]
Pattnaik, Ananya, et al. “Designing of Gradient Scaffolds and Their Applications in Tissue Regeneration.” Biomaterials, vol. 296, May 1, 2023, p. 122078. [cited by applicant]
Mi, Hao-Yang, et al. “In Situ Synthesis of Polyurethane Scaffolds with Tunable Properties by Controlled Crosslinking of Tri-Block Copolymer and Polycaprolactone Trio I for Tissue Regeneration.” Chemical Engineering Jour… [cited by applicant]
Ulery, Brett D. “Biomedical Applications of Biodegradable Polymers.” Journal of Polymer Science Part B: Polymer Physics, vol. 49, No. 12, Jun. 15, 2011, pp. 832-864. Published Jun. 12, 2012 (Jun. 12, 2012). [cited by applicant]
Kaikade, Dhiraj S., et al. “Polyurethane Foams from Vegetable Oil-Based Polyols: A Review.” Polymer Bulletin, vol. 80, No. 3, Mar. 11, 2022, pp. 2239-2261. [cited by applicant]
Habault, Damien, et al. “Light-Triggered Self-Healing and Shape-Memory Polymers.” Chemical Society Reviews, vol. 42, No. 17, Jan. 1, 2013, p. 7244. [cited by applicant]
Peng, Ke, et al. “Light Manipulation for Fabrication of Hydrogels and Their Biological Applications.” Acta Biomaterialia, Elsevier, Amsterdam, NL, vol. 137, Oct. 9, 2021, pp. 20-43. [cited by applicant]
International Search Authority, “International Search Report and Written Opinion of the International Searching Authority,” for related PCT Application No. PCT/IB2024/055986, dated Sep. 10, 2024. [cited by applicant]